These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Search MEDLINE/PubMed
Title: RU 486: an overview of mifepristone and its potential applications. Journal: Contracept Rep; 1993 May; 4(2):7-9. PubMed ID: 12286473. Abstract: RU-486's primary use as an abortifacient stirs controversy in the US. Changes in US policy have opened the door for RU-486 to be made available for research. The Population Council plans on conducting a multicenter clinical trial of RU-486 involving at least 2000 women. This is the first step to obtaining possible approval from the Food and Drug Administration. RU-486 alone has an effectiveness rate of inducing abortion between 80 and 90%. When taken 36 to 48 hours before a prostaglandin (PG) analogue, the rate climbs to about 95%. Possible side effects of RU-486 and the analogue are bleeding, abdominal pain, and cardiovascular problems (rare). More than 100,000 women in France have undergone the RU-486/PG analogue regimen. RU-486 also has contraceptive qualities. If taken every day during the week before ovulation, it prevents ovulation. 12 days of RU-486 administration followed by 10 days of administration of a synthetic progestin also suppresses ovulation. Taking RU-486 during the last 10 to 12 days of the menstrual cycle alters the endometrium, thereby preventing implantation. A single dose of RU-486 during the late luteal phase is about 80% effective at bringing on menses. The aforementioned effects of Ru-486 demonstrate that it may be an effective postcoital contraceptive. Besides, RU-486 has fewer side effects than other postcoital contraceptive regimens. Further, RU-486 softens and dilates the cervix, thus it can be used to induce labor and ease delivery. Evidence suggests that RU-486 may be used to treat hormone-dependent breast tumors, Cushing's syndrome, meningiomas, and endometriosis.[Abstract] [Full Text] [Related] [New Search]